Prognostic factors for colectomy in refractory ulcerative colitis treated with calcineurin inhibitors

Bamba,Shigeki; Andoh,Akira; Imaeda,Hirotsugu; Ban,Hiromitsu; Kobori,Ayako; Mochizuki,Yousuke; Shioya,Makoto; Nishimura,Takashi; Inatomi,Osamu; Sasaki,Masaya; Saitoh,Yasuharu; Tsujikawa,Tomoyuki; Fujiyama,Yoshihide

doi:10.3892/etm.2012.545

Prognostic factors for colectomy in refractory ulcerative colitis treated with calcineurin inhibitors

Authors:
- Shigeki Bamba
- Akira Andoh
- Hirotsugu Imaeda
- Hiromitsu Ban
- Ayako Kobori
- Yousuke Mochizuki
- Makoto Shioya
- Takashi Nishimura
- Osamu Inatomi
- Masaya Sasaki
- Yasuharu Saitoh
- Tomoyuki Tsujikawa
- Yoshihide Fujiyama
View Affiliations

Affiliations: Division of Gastroenterology, Shiga University of Medical Science, Otsu, Shiga, Japan, Division of Mucosal Immunology, Graduate School of Medicine, Shiga University of Medical Science, Otsu, Shiga, Japan, Division of Endoscopy, Shiga University of Medical Science, Otsu, Shiga, Japan, Division of Clinical Nutrition, Shiga University of Medical Science, Otsu, Shiga, Japan, Division of Comprehensive Internal Medicine, Shiga University of Medical Science, Otsu, Shiga, Japan
Published online on: April 11, 2012 https://doi.org/10.3892/etm.2012.545
Pages: 99-104

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Calcineurin inhibitors (CNIs) such as cyclosporin A (CSA) and tacrolimus (FK506) are efficacious in patients with steroid-refractory or steroid-dependent ulcerative colitis (UC). We retrospectively investigated patients with refractory UC treated with CNIs to elucidate the prognostic factors for a colectomy. Data from 59 patients (35 men and 24 women) were analyzed. CSA and FK506 were administered by intravenous infusion and peroral administration, respectively. The efficacy of the CNIs was assessed using Seo's complex integrated disease activity index. Categorical data analyses were also conducted. The results revealed that the response rates for CSA and FK506 were similar (CSA, 66.6%; FK506, 63.6%). However, oral FK506 had a slower onset of action than intravenous CSA. The risk factors for CNI non-responsiveness were: i) more than 10,000 mg of prednisolone used prior to CNI treatment; and ii) positivity for cytomegalovirus antigenemia (C7‑HRP). The factors affecting the rate of colectomy were: i) CNI non-responsiveness; ii) more than 10,000 mg of prednisolone used prior to the initiation of CNI treatment; and iii) positivity for C7‑HRP. The addition of azathioprine (AZA) following CNI treatment significantly reduced the incidence of colectomy. Our results revealed the prognostic factors affecting the efficacy of CNI therapy and the need for colectomy in patients with refractory UC. Importantly, some of these factors may be obtained prior to or shortly following the start of CNI treatment. Furthermore, AZA is an important agent for averting colectomy once a patient responds to CNIs.

View Figures

View References

1	Sandborn W: A critical review of cyclosporin therapy in inflammatory bowel disease. Inflamm Bowel Dis. 1:48–63. 1995.
2	Actis GC, Ottobrelli A, Pera A, et al: Continuously infused cyclosporine at low dose is sufficient to avoid emergency colectomy in acute attacks of ulcerative colitis without the need for high-dose steroids. J Clin Gastroenterol. 17:10–13. 1993. View Article : Google Scholar : PubMed/NCBI
3	Lichtiger S, Present DH, Kornbluth A, et al: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 330:1841–1845. 1994. View Article : Google Scholar : PubMed/NCBI
4	Fellermann K, Tanko Z, Herrlinger KR, et al: Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis. 8:317–324. 2002. View Article : Google Scholar : PubMed/NCBI
5	Ogata H, Matsui T, Nakamura M, et al: A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 55:1255–1262. 2006. View Article : Google Scholar : PubMed/NCBI
6	Bamba S, Tsujikawa T, Inatomi O, et al: Factors affecting the efficacy of cyclosporin A therapy for refractory ulcerative colitis. J Gastroenterol Hepatol. 25:494–498. 2010. View Article : Google Scholar : PubMed/NCBI
7	http://www.info.pmda.go.jp/downfiles/ph/PDF/800126_3999014M1022_3_18.pdfuri
8	Seo M, Okada M, Yao T, Ueki M, Arima S and Okumura M: An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol. 87:971–976. 1992.PubMed/NCBI
9	Travis S, Satsangi J and Lemann M: Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers. Gut. 60:3–9. 2011. View Article : Google Scholar : PubMed/NCBI
10	Meyers S, Lerer PK, Feuer EJ, Johnson JW and Janowitz HD: Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results of a prospective, randomized, double-blind clinical trial. J Clin Gastroenterol. 9:50–54. 1987. View Article : Google Scholar : PubMed/NCBI
11	Truelove SC and Jewell DP: Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet. 1:1067–1070. 1974. View Article : Google Scholar : PubMed/NCBI
12	Oshitani N, Kitano A, Fukushima R, et al: Predictive factors for the response of ulcerative colitis patients during the acute-phase treatment. Digestion. 46:107–113. 1990. View Article : Google Scholar : PubMed/NCBI
13	Chakravarty BJ: Predictors and the rate of medical treatment failure in ulcerative colitis. Am J Gastroenterol. 88:852–855. 1993.PubMed/NCBI
14	Turner D, Mack D, Leleiko N, et al: Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology. 138:2282–2291. 2010. View Article : Google Scholar : PubMed/NCBI
15	Carbonnel F, Gargouri D, Lemann M, et al: Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther. 14:273–279. 2000. View Article : Google Scholar : PubMed/NCBI
16	Kumar S, Ghoshal UC, Aggarwal R, Saraswat VA and Choudhuri G: Severe ulcerative colitis: prospective study of parameters determining outcome. J Gastroenterol Hepatol. 19:1247–1252. 2004. View Article : Google Scholar : PubMed/NCBI
17	Elloumi H, Ben Abdelaziz A, Derbel F, et al: Predictive factors of glucocorticosteroid treatment failure in severe acute idiopathic colitis. Acta Gastroenterol Belg. 68:226–229. 2005.PubMed/NCBI
18	Oshitani N, Matsumoto T, Jinno Y, et al: Prediction of short-term outcome for patients with active ulcerative colitis. Dig Dis Sci. 45:982–986. 2000. View Article : Google Scholar : PubMed/NCBI
19	Cacheux W, Seksik P, Lemann M, et al: Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol. 103:637–642. 2008. View Article : Google Scholar : PubMed/NCBI
20	Vega R, Bertran X, Menacho M, et al: Cytomegalovirus infection in patients with inflammatory bowel disease. Am J Gastroenterol. 94:1053–1056. 1999. View Article : Google Scholar : PubMed/NCBI
21	Loftus EV Jr, Alexander GL and Carpenter HA: Cytomegalovirus as an exacerbating factor in ulcerative colitis. J Clin Gastroenterol. 19:306–309. 1994. View Article : Google Scholar : PubMed/NCBI
22	Cottone M, Pietrosi G, Martorana G, et al: Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn’s colitis. Am J Gastroenterol. 96:773–775. 2001.
23	Matsuoka K, Iwao Y, Mori T, et al: Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients. Am J Gastroenterol. 102:331–337. 2007. View Article : Google Scholar : PubMed/NCBI
24	Yoshino T, Nakase H, Ueno S, et al: Usefulness of quantitative real-time PCR assay for early detection of cytomegalovirus infection in patients with ulcerative colitis refractory to immunosuppressive therapies. Inflamm Bowel Dis. 13:1516–1521. 2007. View Article : Google Scholar : PubMed/NCBI
25	Kuwabara A, Okamoto H, Suda T, Ajioka Y and Hatakeyama K: Clinicopathologic characteristics of clinically relevant cytomegalovirus infection in inflammatory bowel disease. J Gastroenterol. 42:823–829. 2007. View Article : Google Scholar
26	Yoshiyama S, Miki C, Okita Y, Araki T, Uchida K and Kusunoki M: Neutrophil-related immunoinf lammatory disturbance in steroid-overdosed ulcerative colitis patients. J Gastroenterol. 43:789–797. 2008. View Article : Google Scholar : PubMed/NCBI